Augmenix

Category Archives

Augmenix’ SpaceOAR® System Experiences Rapid U.S. Adoption

WALTHAM, Mass.--(Business Wire)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following Read more...

Augmenix Announces Publication of SpaceOAR® System Clinical Trial Results in Leading Radiation Oncology Journal

Pivotal Study Demonstrates Product Safety and Patient Benefits in Men Undergoing Prostate Radiotherapy WALTHAM, Mass.—Augmenix, Inc., a medical Read more...

Provision first proton therapy center using new product to benefit prostate cancer patients

KNOXVILLE, Tenn. (WVLT)-- Provision Center for Proton Therapy is helping pioneer a new product that will help further protect prostate cancer patients Read more...

New prostate treatment protects from radiation effects

CHARDON, Ohio -- Two days ago, the FDA approved a new product that protects prostate cancer patients from the side effects of radiation. It's called Read more...

Augmenix Announces Clearance of SpaceOAR® System

Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced Read more...

Augmenix aims for profitability with $10.8M Series D round as Varian acquisition option expires

Protecting patients from unnecessary exposure to radiation is the aim of start-up Augmenix. To advance its efforts and achieve profitability, the company Read more...

Augmenix Announces Completion of Series D Financing

Augmenix Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy today announced Read more...

Augmenix Receives CE Mark Approval for TraceIT® Fiducial Marker and TraceIT® Gel System

Augmenix, Inc. today announced that it has received European commercial approval for both TraceIT Fiducial Marker and TraceIT Gel System, absorbable markers Read more...

Augmenix Receives FDA Clearance to Market its TraceIT™ Tissue Marker

Augmenix, Inc., an innovative medical technology company focused on utilizing hydrogel technology in the fields of tissue marking and radiation oncology, Read more...

Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix

Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix Agreement creates opportunity for improving outcomes in radiation Read more...

Page 2 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184